The long non-coding rna dnm3os is a reservoir ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
The long non-coding rna dnm3os is a reservoir of fibromirs with major functions in lung fibroblast response to tgf-? and pulmonary fibrosis
Author(s) :
Savary, Gregoire [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Diazzi, Serena [Auteur]
Centre méditerranéen de médecine moléculaire [C3M]
Buscot, Matthieu [Auteur]
Nottet, Nicolas [Auteur]
Fassy, Julien [Auteur]
Courcot, Elisabeth [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Henaoui, Imene-Sarah [Auteur]
Lemaire, Julie [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Martis, Nihal [Auteur]
Van Der Hauwaert, Cynthia [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - EA 4483
Pons, Nicolas [Auteur]
Magnone, Virginie [Auteur]
Leroy, Sylvie [Auteur]
Hofman, Veronique [Auteur]
Plantier, Laurent [Auteur]
Lebrigand, Kevin [Auteur]
Paquet, Agnes [Auteur]
Lino Cardenas, Christian L. [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Vassaux, Georges [Auteur]
Hofman, Paul [Auteur]
Gunther, Andreas [Auteur]
Crestani, Bruno [Auteur]
Wallaert, Benoit [Auteur]
Rezzonico, Roger [Auteur]
Brousseau, Thierry [Auteur]
Glowacki, Francois [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Bellusci, Saverio [Auteur]
Perrais, Michael [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Broly, Franck [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
barbry, pascal [Auteur]
Marquette, Charles-Hugo [Auteur]
Cauffiez, Christelle [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - EA 4483
Mari, Bernard [Auteur]
Pottier, Nicolas [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - EA 4483
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Diazzi, Serena [Auteur]
Centre méditerranéen de médecine moléculaire [C3M]
Buscot, Matthieu [Auteur]
Nottet, Nicolas [Auteur]
Fassy, Julien [Auteur]
Courcot, Elisabeth [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Henaoui, Imene-Sarah [Auteur]
Lemaire, Julie [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Martis, Nihal [Auteur]
Van Der Hauwaert, Cynthia [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - EA 4483
Pons, Nicolas [Auteur]
Magnone, Virginie [Auteur]
Leroy, Sylvie [Auteur]
Hofman, Veronique [Auteur]
Plantier, Laurent [Auteur]
Lebrigand, Kevin [Auteur]
Paquet, Agnes [Auteur]
Lino Cardenas, Christian L. [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Vassaux, Georges [Auteur]
Hofman, Paul [Auteur]
Gunther, Andreas [Auteur]
Crestani, Bruno [Auteur]
Wallaert, Benoit [Auteur]
Rezzonico, Roger [Auteur]
Brousseau, Thierry [Auteur]
Glowacki, Francois [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Bellusci, Saverio [Auteur]
Perrais, Michael [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Broly, Franck [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
barbry, pascal [Auteur]
Marquette, Charles-Hugo [Auteur]
Cauffiez, Christelle [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - EA 4483
Mari, Bernard [Auteur]
Pottier, Nicolas [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - EA 4483
Journal title :
American Journal of Respiratory and Critical Care Medicine
Abbreviated title :
Am. J. Respir. Crit. Care Med.
Volume number :
200
Pages :
184-198
Publisher :
ATS Journal
Publication date :
2019-04-09
ISSN :
1535-4970
Keyword(s) :
fibroblast
miRNA
lncRNA
pulmonary fibrosis
TGF-beta
miRNA
lncRNA
pulmonary fibrosis
TGF-beta
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Rationale: Given the paucity of effective treatments for idiopathic pulmonary fibrosis (IPF), new insights into the deleterious mechanisms controlling lung fibroblast activation, the key cell type driving the fibrogenic ...
Show more >Rationale: Given the paucity of effective treatments for idiopathic pulmonary fibrosis (IPF), new insights into the deleterious mechanisms controlling lung fibroblast activation, the key cell type driving the fibrogenic process, are essential to develop new therapeutic strategies. TGF-β (transforming growth factor-β) is the main profibrotic factor, but its inhibition is associated with severe side effects because of its pleiotropic role. Objectives: To determine if downstream noncoding effectors of TGF-β in fibroblasts may represent new effective therapeutic targets whose modulation may be well tolerated. Methods: We investigated the whole noncoding fraction of TGF-β–stimulated lung fibroblast transcriptome to identify new genomic determinants of lung fibroblast differentiation into myofibroblasts. Differential expression of the long noncoding RNA (lncRNA) DNM3OS (dynamin 3 opposite strand) and its associated microRNAs (miRNAs) was validated in a murine model of pulmonary fibrosis and in IPF tissue samples. Distinct and complementary antisense oligonucleotide–based strategies aiming at interfering with DNM3OS were used to elucidate the role of DNM3OS and its associated miRNAs in IPF pathogenesis. Measurements and Main Results: We identified DNM3OS as a fibroblast-specific critical downstream effector of TGF-β–induced lung myofibroblast activation. Mechanistically, DNM3OS regulates this process in trans by giving rise to three distinct profibrotic mature miRNAs (i.e., miR-199a-5p/3p and miR-214-3p), which influence SMAD and non-SMAD components of TGF-β signaling in a multifaceted way. In vivo, we showed that interfering with DNM3OS function not only prevents lung fibrosis but also improves established pulmonary fibrosis. Conclusions: Pharmacological approaches aiming at interfering with the lncRNA DNM3OS may represent new effective therapeutic strategies in IPF.Show less >
Show more >Rationale: Given the paucity of effective treatments for idiopathic pulmonary fibrosis (IPF), new insights into the deleterious mechanisms controlling lung fibroblast activation, the key cell type driving the fibrogenic process, are essential to develop new therapeutic strategies. TGF-β (transforming growth factor-β) is the main profibrotic factor, but its inhibition is associated with severe side effects because of its pleiotropic role. Objectives: To determine if downstream noncoding effectors of TGF-β in fibroblasts may represent new effective therapeutic targets whose modulation may be well tolerated. Methods: We investigated the whole noncoding fraction of TGF-β–stimulated lung fibroblast transcriptome to identify new genomic determinants of lung fibroblast differentiation into myofibroblasts. Differential expression of the long noncoding RNA (lncRNA) DNM3OS (dynamin 3 opposite strand) and its associated microRNAs (miRNAs) was validated in a murine model of pulmonary fibrosis and in IPF tissue samples. Distinct and complementary antisense oligonucleotide–based strategies aiming at interfering with DNM3OS were used to elucidate the role of DNM3OS and its associated miRNAs in IPF pathogenesis. Measurements and Main Results: We identified DNM3OS as a fibroblast-specific critical downstream effector of TGF-β–induced lung myofibroblast activation. Mechanistically, DNM3OS regulates this process in trans by giving rise to three distinct profibrotic mature miRNAs (i.e., miR-199a-5p/3p and miR-214-3p), which influence SMAD and non-SMAD components of TGF-β signaling in a multifaceted way. In vivo, we showed that interfering with DNM3OS function not only prevents lung fibrosis but also improves established pulmonary fibrosis. Conclusions: Pharmacological approaches aiming at interfering with the lncRNA DNM3OS may represent new effective therapeutic strategies in IPF.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Institut Pasteur de Lille
Université de Lille
CNRS
Institut Pasteur de Lille
Université de Lille
Collections :
Submission date :
2022-02-02T10:24:04Z
2024-02-28T09:04:10Z
2024-02-28T09:04:10Z
Files
- savary et al.pdf
- Version éditeur
- Restricted access
- Access the document